Literature DB >> 8843528

Ambulatory blood pressure on and off continuous positive airway pressure therapy for the sleep apnea/hypopnea syndrome: effects in "non-dippers".

H M Engleman1, K Gough, S E Martin, R N Kingshott, P L Padfield, N J Douglas.   

Abstract

Ambulatory blood pressure (BP) monitoring was performed in 13 patients with the sleep apnea/ hypopnea syndrome (SAHS) during a randomized, placebo controlled crossover trial of the effects of continuous positive airway pressure (CPAP) therapy. BP was monitored at half-hourly intervals for a 24-hour period both on CPAP and on an oral placebo, each given for a minimum of 3 weeks. Objective effective CPAP use averaged 4.3 hours per night. Weight and anti-hypertensive medications remained stable over the study period. Systolic, diastolic and mean arterial BP for 24-hour, daytime and nighttime periods were not significantly different on placebo compared to CPAP. Those patients with no significant overnight fall in BP on placebo ("non-dippers") showed a significant improvement in daytime mean arterial BP on CPAP (98 +/- 4 mm Hg) compared to placebo (102 +/- 4 mm Hg; p = 0.01). These findings, in a well-controlled trial, suggest that BP is not reduced by CPAP in a heterogeneous group of SAHS patients, but it may be selectively improved in those patients most at risk for cardiovascular morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843528     DOI: 10.1093/sleep/19.5.378

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  30 in total

Review 1.  CPAP therapy: outcomes and patient use.

Authors:  N J Douglas; H M Engleman
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  Sleep . 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension.

Authors:  G V Robinson; J R Stradling; R J O Davies
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

3.  The ineffectiveness of magnotherapy in a patient with obstructive sleep apnea syndrome and cardiovascular comorbidity.

Authors:  Yaron Dagan; Katy Borodkin
Journal:  Sleep Breath       Date:  2004-12       Impact factor: 2.816

4.  The effect of oral appliance therapy on blood pressure in patients with obstructive sleep apnea.

Authors:  Ryo Otsuka; Fernanda Ribeiro de Almeida; Alan A Lowe; Wolfgang Linden; Frank Ryan
Journal:  Sleep Breath       Date:  2006-03       Impact factor: 2.816

Review 5.  Positive pressure therapy: a perspective on evidence-based outcomes and methods of application.

Authors:  Mark H Sanders; Josep M Montserrat; Ramon Farré; Rachel J Givelber
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

6.  Guidelines for diagnosing and treating sleep related breathing disorders in adults and children (Part 2: treatment).

Authors:  V Tsara; A Amfilochiou; M J Papagrigorakis; D Georgopoulos; E Liolios; C Alexopoulou; C Maniou; P Kithreotis; G Trakada; F Synodinos; G Vilos; P Steiropoulos
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 7.  Cardiovascular aspects of obstructive sleep apnoea and their relevance to the assessment of the efficacy of nasal continuous positive airway pressure therapy.

Authors:  R J Davies
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

8.  Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment.

Authors:  Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

9.  Treating obstructive sleep apnea with positive pressure therapy.

Authors:  Ninon Pachikara; Reena Mehra
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

10.  Variables affecting the change in systemic blood pressure in response to nasal CPAP in obstructive sleep apnea patients.

Authors:  Junaid Malik; Christopher L Drake; David W Hudgel
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.